Neuphoria Therapeutics, Inc. (NEUP)
3.06
-0.30
(-8.93%)
USD |
NASDAQ |
Oct 29, 16:00
3.08
+0.02
(+0.65%)
After-Hours: 20:00
Neuphoria Therapeutics Enterprise Value : -3.273M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -3.273M |
| October 28, 2026 | -1.649M |
| October 27, 2026 | -1.487M |
| October 26, 2026 | -1.541M |
| October 23, 2026 | -1.216M |
| October 22, 2026 | -0.9999M |
| October 21, 2026 | -0.9999M |
| October 20, 2026 | -1.487M |
| October 19, 2026 | -1.920M |
| October 16, 2026 | -1.974M |
| October 15, 2026 | -1.920M |
| October 14, 2026 | -2.299M |
| October 13, 2026 | -1.487M |
| October 12, 2026 | -1.866M |
| October 09, 2026 | -1.649M |
| October 08, 2026 | -1.703M |
| October 07, 2026 | -1.325M |
| October 06, 2026 | -1.162M |
| October 05, 2026 | -1.162M |
| October 02, 2026 | -1.054M |
| October 01, 2026 | -0.8375M |
| September 30, 2026 | -0.567M |
| September 29, 2026 | -0.5129M |
| September 28, 2026 | -0.08M |
| September 25, 2026 | -0.08M |
| Date | Value |
|---|---|
| September 24, 2026 | -0.08M |
| September 23, 2026 | 0.0824M |
| September 22, 2026 | 0.38M |
| September 21, 2026 | 0.2447M |
| September 18, 2026 | 0.1906M |
| September 17, 2026 | 0.2718M |
| September 16, 2026 | 0.4071M |
| September 15, 2026 | 0.6235M |
| September 14, 2026 | 0.7317M |
| September 11, 2026 | 0.3529M |
| September 10, 2026 | 0.3529M |
| September 09, 2026 | 0.4612M |
| September 08, 2026 | 0.4612M |
| September 04, 2026 | 0.5694M |
| September 03, 2026 | 0.5153M |
| September 02, 2026 | 0.4612M |
| September 01, 2026 | 0.6776M |
| August 31, 2026 | 0.5153M |
| August 28, 2026 | 0.5153M |
| August 27, 2026 | 0.5694M |
| August 26, 2026 | 1.056M |
| August 25, 2026 | 1.056M |
| August 24, 2026 | 1.543M |
| August 21, 2026 | 1.327M |
| August 20, 2026 | 1.543M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 566.80M |
| Amgen, Inc. | 292.39B |
| Anika Therapeutics, Inc. | 278.45M |
| BioCryst Pharmaceuticals, Inc. | 2.658B |
| Imunon, Inc. | 4.867M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.904M |
| Revenue (Quarterly) | 1.174M |
| Total Expenses (Quarterly) | 6.079M |
| EPS Diluted (Quarterly) | -0.9063 |
| Gross Profit Margin (Quarterly) | 85.89% |
| Profit Margin (Quarterly) | -417.7% |
| Earnings Yield | -202.1% |
| Normalized Earnings Yield | -159.57 |